Noble Financial Offers Insights on Nutriband's FY2025 Earnings Forecast

Nutriband Inc. (NASDAQ:NTRB) – In a recent research note, Noble Financial analysts provided their projections for Nutriband's earnings for the fiscal year 2025. Analyst R. Leboyer anticipates that Nutriband will report earnings of ($0.60) per share for the year. This information was shared with clients and investors on Wednesday, January 22nd.

Noble Financial has placed an "Outperform" rating on Nutriband's stock, pairing it with a price target of $13.00. The analysts also made estimates for the company’s quarterly earnings, expecting Q4 2025 to show earnings of ($0.12) per share, Q1 2026 at ($0.13) per share, Q2 2026 at ($0.16) per share, Q3 2026 at ($0.19) per share, Q4 2026 at ($0.08) per share, and FY2026 earnings at ($0.56) per share. Looking further ahead, they predict FY2027 earnings at $1.45 per share and FY2028 earnings rising to $3.66 per share.

Nutriband Stock Performance Overview

The stock of Nutriband opened at $8.53 on Friday. Over the past year, shares have fluctuated, reaching a low of $2.22 and a high of $11.78. The company boasts a current ratio of 4.96 and a quick ratio of 4.83, alongside a low debt-to-equity ratio of 0.01. Nutriband's stock has been trading with a fifty-day simple moving average of $4.66 and a two-hundred-day simple moving average of $5.46. As of now, the market capitalization stands at approximately $94.77 million, with a price-to-earnings ratio of -12.01 and a beta of 0.99.

Most recently, Nutriband released its quarterly earnings on December 3rd, where it reported an earnings per share (EPS) of ($0.12) for the quarter. The company is experiencing significant financial challenges, demonstrated by a negative net margin of 338.51% and a negative return on equity of 54.49%.

Nutriband Company Overview

Nutriband Inc. focuses on developing a range of transdermal pharmaceutical products. Their primary product in the pipeline is AVERSA fentanyl, designed as an abuse-deterrent system that offers clinicians and patients an extended-release method for managing chronic pain requiring constant opioid therapy.

Additional Insights and Considerations

Investors interested in Nutriband should keep a close eye on upcoming quarterly reports and future earnings forecasts as the company works toward improving its financial standing and capitalizing on its product development.

Nutriband, Earnings, Forecast